Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly-guided therapy versus platinum chemotherapy in cancer of unknown primary
NCT03498521Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Countries
- 33
01
Overview
Phase 2, randomised, open-label trial in cancer of unknown primary site (CUP) (2 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival at 3.4 years. Started Jul 2018; status: completed.
02
Conditions
cancer of unknown primary site (CUP)
Beyond the preview
Go deeper on NCT03498521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498521.